Macrogenics (MGNX) Current Leases (2019 - 2026)
Macrogenics (MGNX) posted quarterly Current Leases of $5.2 million for Q1 2026, down 2.85% year-over-year from $5.4 million in Q1 2025, and up 0.71% quarter-over-quarter from $5.2 million in Q4 2025.
Macrogenics (MGNX) Current Leases (2019 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Current Leases for 8 consecutive years, with $5.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Leases fell 2.85% year-over-year to $5.2 million; the TTM figure through Mar 2026 stood at $5.2 million (down 2.85% YoY), while the FY2025 annual figure was $5.2 million, up 6.44% from the prior year.
- Current Leases grew to $5.2 million in Q1 2026 per MGNX's latest filing, from $5.2 million in the prior quarter.
- Across five years, Current Leases topped out at $5.4 million in Q1 2025 and bottomed at $3.8 million in Q4 2023.
- Historically, Current Leases has averaged $4.7 million across 5 years, with a median of $4.8 million in 2022.
- Annual changes were most pronounced in 2023 — Current Leases decreased 21.81% — and 2025, when it jumped 31.38%.
- Macrogenics' Current Leases stood at $4.7 million in 2022, then retreated by 20.12% to $3.8 million in 2023, then advanced by 28.85% to $4.9 million in 2024, then climbed by 6.44% to $5.2 million in 2025, then grew by 0.71% to $5.2 million in 2026.
- Business Quant data shows MGNX's Current Leases at $5.2 million in Q1 2026, $5.2 million in Q4 2025, and $5.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - | 5.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.21 Mn |
| Dec 31, 2025 | 5.18 Mn |
| Sep 30, 2025 | 5.14 Mn |
| Jun 30, 2025 | 5.12 Mn |
| Mar 31, 2025 | 5.37 Mn |
| Dec 31, 2024 | 4.86 Mn |
| Sep 30, 2024 | 4.74 Mn |
| Jun 30, 2024 | 4.41 Mn |
| Mar 31, 2024 | 4.09 Mn |
| Dec 31, 2023 | 3.78 Mn |
| Sep 30, 2023 | 3.93 Mn |
| Jun 30, 2023 | 4.16 Mn |
| Mar 31, 2023 | 4.42 Mn |
| Dec 31, 2022 | 4.73 Mn |
| Sep 30, 2022 | 5.02 Mn |
| Jun 30, 2022 | 4.94 Mn |
| Mar 31, 2022 | 4.84 Mn |
| Dec 31, 2021 | 4.68 Mn |
| Sep 30, 2021 | 4.52 Mn |
| Jun 30, 2021 | 4.37 Mn |